aod9604 banned AOD-9604 'not performance enhancing': Essendon AOD 9604: Peptide Claims vs
Description
The peptides targeted mechanism of action on adipose tissue minimizes systemic effects and potential complications
up to 500 mcg if needed
Common Side Effects When side effects occurred, they were typically mild, transient, and similar in frequency to placebo groups: Reported Adverse Effects Most Common (occurring in small percentage of participants): Mild to moderate headaches (most frequently reported, often resolving with continued use) Injection site reactions (minor redness, swelling, or irritation at injection site) Gastrointestinal effects (particularly at higher oral doses: mild nausea, diarrhea, flatulence) Fatigue (reported occasionally during initial adaptation period) Rare Events: One case of chest tightness was deemed possibly related to treatment in safety trials
